Buffett-Style Value Investment Analysis: 新和成 (002001)

(Zhejiang NHU Co., Ltd.)

---

1️⃣ Circle of Competence Analysis

1.1 Is the Company's Business Easy to Understand?

✅ What are the products?

According to the 2024 Annual Report, the company focuses on fine chemicals and builds its business around four major segments:

• Nutrition (Vitamins & Methionine)
• Flavor & Fragrance
• New Materials
• APIs (Active Pharmaceutical Ingredients) :contentReference[oaicite:0]{index=0}

The core revenue historically comes from:

• Vitamins (A, E, B series, etc.)
• Methionine (feed additive)
• Selected high-value fine chemicals

This is a classic bulk fine chemical + scale manufacturing business, not a financialized business model.

---

✅ Who are the customers?

• Feed producers
• Food & beverage companies
• Pharmaceutical companies
• Fragrance & consumer product companies

The business is B2B and industrial in nature, with high export exposure.

---

✅ Revenue Transparency

Operating revenue (2024):

• 21.61 billion RMB :contentReference[oaicite:1]{index=1}
• Clear breakdown by segments
• Revenue driven by volume × price cycles

No financial engineering; pure industrial manufacturing.

---

✅ Industry Type

• Fine chemical manufacturing
• Nutritional additives
• Industrial specialty materials

This is within circle of competence for value investors familiar with cyclical commodity-chemicals.

---

1.2 Is the Business Logic Clear for 10 Years?

Industry Characteristics

From the report:

• Vitamins: Slow steady demand growth
• Supply highly concentrated in China (85.9% global production in 2024) :contentReference[oaicite:2]{index=2}
• Methionine: High technical barrier, capital intensive :contentReference[oaicite:3]{index=3}

This is a cyclical oligopoly industry.

---

Market Share & Position

China dominates vitamin supply. NHU is one of:

• Largest vitamin producers globally
• Major methionine capacity player

Industry structure favors scale leaders.

---

Demand Stability

• Feed demand tied to livestock cycle
• Human nutrition tied to population aging
• Moderate long-term growth

However:
⚠ Prices fluctuate strongly due to supply/demand cycles.

---

📌 Conclusion (Circle of Competence):

✔ Understandable
✔ Predictable over long cycle
✔ Cyclical earnings

Inside circle — but requires understanding of commodity cycles.

---

2️⃣ Durable Competitive Advantage (Moat)

2.1 Brand

In bulk chemicals:

• Customers buy based on price + reliability
• Limited brand premium

❌ Weak brand moat

---

2.2 Cost Advantage

Key strength:

• Large-scale production
• Integrated upstream processes
• Chinese cost advantage
• Methionine has high technical barrier :contentReference[oaicite:4]{index=4}

Scale lowers per-unit cost.

✔ Sustainable cost moat (medium strength)

---

2.3 Switching Costs

For feed-grade vitamins:

• Switching is easy if quality equivalent

Low switching cost.

---

2.4 Network Effect

None.

---

2.5 Scale Advantage

Operating margin expands sharply during upcycle.

2024 Net Profit:

• 5.87 billion RMB (117% YoY growth) :contentReference[oaicite:5]{index=5}

ROE:

• 21.78% in 2024 :contentReference[oaicite:6]{index=6}

Scale + cycle leverage creates strong profit elasticity.

---

📌 Moat Judgment:
Medium (Cost + Scale Moat)
Not Coca-Cola level. But strong within commodity chemicals.

---

3️⃣ Management

3.1 Integrity

• Clean audit history
• No accounting irregularities reported
• Stable leadership

No red flags in annual reports.

---

3.2 Execution

Revenue:

• 2023: 15.12B RMB :contentReference[oaicite:7]{index=7}
• 2024: 21.61B RMB :contentReference[oaicite:8]{index=8}

Profit:

• 2023: 2.70B RMB :contentReference[oaicite:9]{index=9}
• 2024: 5.87B RMB :contentReference[oaicite:10]{index=10}

Strong recovery in upcycle.

---

3.3 Alignment

• Consistent dividend policy
• 5.00 RMB per 10 shares dividend in 2024 :contentReference[oaicite:11]{index=11}

Capital allocation disciplined.

---

📌 Management Rating: Above Average

---

4️⃣ Financials

4.1 Profitability

| Year | Revenue | Net Profit | ROE | |------|----------|------------|------| | 2022 | 15.93B | 3.62B | 16.08% :contentReference[oaicite:12]{index=12} | | 2023 | 15.12B | 2.70B | 11.24% :contentReference[oaicite:13]{index=13} | | 2024 | 21.61B | 5.87B | 21.78% :contentReference[oaicite:14]{index=14} |

Cyclical but strong in upcycle.

---

4.2 Returns

2024 ROE: 21.78% :contentReference[oaicite:15]{index=15}

This exceeds cost of capital.

---

4.3 Cash Flow

2024 Operating Cash Flow:

• 7.07B RMB :contentReference[oaicite:16]{index=16}

Strong FCF generation.

---

4.4 Balance Sheet

2024:

• Total Assets: 42.99B RMB :contentReference[oaicite:17]{index=17}
• Net Assets: 29.32B RMB :contentReference[oaicite:18]{index=18}

Conservative leverage.

---

📌 Financial Assessment:
Strong but cyclical. Balance sheet healthy.

---

5️⃣ Intrinsic Value

(The following content is exclusive to subscribers.)